GRDN

Guardian Pharmacy Services Inc

Add to Watchlist

Advanced Chart

20.780

+0.23(1.119%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.930

Open

20.620

VWAP

Vol

52.46K

Mkt Cap

1.30B

Low

20.370

Amount

EV/EBITDA(TTM)

Total Shares

63.29M

1.29B

EV/OCF(TTM)

P/S(TTM)

1.00

Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its services include GuardianShield, provider services, and others. Its Guardian Compass platform offers insights to enhance efficiencies for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers. It serves assisted living and memory care, hospice care and others.

2 Analyst Rating

34.74% Upside

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

34.74% Upside

Current: 20.780

Low

28.00

Averages

28.00

High

28.00

34.74% Upside

Current: 20.780

Low

28.00

Averages

28.00

High

28.00

Truist

Buy

maintain

$25 -> $28

2025-05-19

Reason

Truist

Price Target

$25 -> $28

2025-05-19

maintain

Buy

Reason

Raymond James

John Ransom

Outperform

maintain

$25 -> $28

2025-05-14

Reason

Raymond James

John Ransom

Price Target

$25 -> $28

2025-05-14

maintain

Outperform

Reason

Raymond James analyst John Ransom raised the firm's price target on Guardian Pharmacy to $28 from $25 and keeps an Outperform rating on the shares. The company's Q1 results were ahead of the firm's model on revenue, but $600,000 below on EBITDA due to some pull-forward on Heartland integration costs and a slight miss on seasonality, the analyst tells investors in a research note. This was a solid quarter with no major surprises outside of the small seasonality change, and Raymond James continues to like Guardian for its solid organic and inorganic growth potential, clean balance sheet with dry powder for M&A, and performance of operational execution.

Truist Securities

David Macdonald

Strong Buy

Maintains

$24 → $25

2025-04-11

Reason

Truist Securities

David Macdonald

Price Target

$24 → $25

2025-04-11

Maintains

Strong Buy

Reason

Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $25 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.

Truist Securities

David Macdonald

Strong Buy

Maintains

$22 → $24

2024-11-15

Reason

Truist Securities

David Macdonald

Price Target

$22 → $24

2024-11-15

Maintains

Strong Buy

Reason

Stephens & Co.

Scott Fidel

Buy

Initiates

$21

2024-10-22

Reason

Stephens & Co.

Scott Fidel

Price Target

$21

2024-10-22

Initiates

Buy

Reason

Truist Securities

David Macdonald

Strong Buy

Initiates

$22

2024-10-21

Reason

Truist Securities

David Macdonald

Price Target

$22

2024-10-21

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 21.75, compared to its 5-year average forward P/E of 24.14. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

24.14

Current PE

21.75

Overvalued PE

26.63

Undervalued PE

21.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

14.64

Current EV/EBITDA

13.50

Overvalued EV/EBITDA

15.90

Undervalued EV/EBITDA

13.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.02

Current PS

0.98

Overvalued PS

1.12

Undervalued PS

0.93